Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome | Aplastic Anemia & MDS International Foundation
  1. Treatments
  2. Clinical Trials
  3. Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome
Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome

Clinical Trial: NCT01772420

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
https://clinicaltrials.gov/ct2/show/NCT01772420
Purpose: 

This phase II trial studies how well lenalidomide and eltrombopag olamine works in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.

Status: 
Recruiting
Study Date: 
Mon, 10/01/2012 to Sun, 10/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Lenalidomide
Intervention: 
Drug: Eltrombopag Olamine Given PO Other Names: Promacta SB-497115-GR Other: Laboratory Biomarker Analysis Correlative studies Drug: Lenalidomide Given PO Other Names: CC-5013 CC5013 CDC 501 Revlimid